Comparing Halozyme Therapeutics (NASDAQ:HALO) and Alliqua BioMedical (OTCMKTS:ADYX)

Halozyme Therapeutics (NASDAQ:HALO) and Alliqua BioMedical (OTCMKTS:ADYX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Halozyme Therapeutics and Alliqua BioMedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	47.28%	150.85%	29.19%
Alliqua BioMedical	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Halozyme Therapeutics and Alliqua BioMedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	8	4	0	2.33
Alliqua BioMedical	0	0	0	0	0.00

Halozyme Therapeutics currently has a consensus price target of $73.11, indicating a potential upside of 10.44%. Given Halozyme Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Alliqua BioMedical.

Institutional & Insider Ownership

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 17.4% of Alliqua BioMedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Halozyme Therapeutics and Alliqua BioMedical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.18 billion	6.57	$444.09 million	$4.37	15.15
Alliqua BioMedical	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than Alliqua BioMedical.

Summary

Halozyme Therapeutics beats Alliqua BioMedical on 8 of the 9 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

About Alliqua BioMedical

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.